167 related articles for article (PubMed ID: 35121632)
1. There is no role for hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.
Schwameis R; Chiva L; Harter P
Int J Gynecol Cancer; 2022 Apr; 32(4):578. PubMed ID: 35121632
[No Abstract] [Full Text] [Related]
2. Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian Cancer.
Wethington SL; Armstrong DK; Johnston FM
JAMA Surg; 2022 May; 157(5):383. PubMed ID: 35262650
[No Abstract] [Full Text] [Related]
3. Hyperthermic intraperitoneal chemotherapy in epithelial ovarian cancer: current evidence-based indications.
Pareja R
Int J Gynecol Cancer; 2023 May; 33(5):841-842. PubMed ID: 36963802
[No Abstract] [Full Text] [Related]
4. Hyperthermic intraperitoneal chemotherapy for treating ovarian cancer.
Gajarawala S; Pelkowski J; Dorian R; Stanton A; Dinh T
JAAPA; 2021 Aug; 34(8):50-53. PubMed ID: 34320542
[TBL] [Abstract][Full Text] [Related]
5. Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer.
Kim SI; Kim JW
ESMO Open; 2021 Jun; 6(3):100149. PubMed ID: 33984680
[TBL] [Abstract][Full Text] [Related]
6. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer.
Mutlu Sütcüoğlu B; Sütcüoğlu O
Lancet Oncol; 2023 Dec; 24(12):e457. PubMed ID: 38039999
[No Abstract] [Full Text] [Related]
7. The Debatable Role of HIPEC in Ovarian Cancer.
Paulino E; Melo AC
Ann Surg Oncol; 2022 May; 29(5):3353-3354. PubMed ID: 35254576
[No Abstract] [Full Text] [Related]
8. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
Gelissen JH; Adjei NN; McNamara B; Mutlu L; Harold JA; Clark M; Altwerger G; Dottino PR; Huang GS; Santin AD; Azodi M; Ratner E; Schwartz PE; Andikyan V
Ann Surg Oncol; 2023 Sep; 30(9):5597-5609. PubMed ID: 37358686
[TBL] [Abstract][Full Text] [Related]
9. Translational and pharmacological principles of hyperthermic intraperitoneal chemotherapy for ovarian cancer.
Vos LMC; Aronson SL; van Driel WJ; Huitema ADR; Schagen van Leeuwen JH; Lok CAR; Sonke GS
Best Pract Res Clin Obstet Gynaecol; 2022 Jan; 78():86-102. PubMed ID: 34565676
[TBL] [Abstract][Full Text] [Related]
10. Combining HIPEC to Interval Surgery in Ovarian Cancer? One Step Forward with a Second Randomized Study: Comment on "Cytoreductive Surgery with or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer-A Phase 3 Clinical Trial".
Noiret B; Bakrin N; Eveno C
Ann Surg Oncol; 2022 May; 29(5):3357-3358. PubMed ID: 35192155
[No Abstract] [Full Text] [Related]
11. Are We Ready for Hyperthermic Intraperitoneal Chemotherapy in the Upfront Treatment of Ovarian Cancer?
Alter R; Turaga K; Lengyel E
JAMA Netw Open; 2020 Aug; 3(8):e2014184. PubMed ID: 32840618
[No Abstract] [Full Text] [Related]
12. [Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer].
Schmalfeldt B
Chirurgie (Heidelb); 2022 Dec; 93(12):1144-1151. PubMed ID: 36201013
[TBL] [Abstract][Full Text] [Related]
13. Hyperthermic intraperitoneal chemotherapy (HIPEC) for gynecological cancer.
Tsuyoshi H; Inoue D; Kurokawa T; Yoshida Y
J Obstet Gynaecol Res; 2020 Sep; 46(9):1661-1671. PubMed ID: 32715605
[TBL] [Abstract][Full Text] [Related]
14. The necessity to adhere to evidence-based indications for hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with ovarian cancer.
Brennan DJ; Driel WJV; Zivanovic O
Int J Gynecol Cancer; 2023 May; 33(5):851-852. PubMed ID: 36898700
[No Abstract] [Full Text] [Related]
15. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer - Authors' reply.
Aronson SL; Sonke GS; van Driel WJ
Lancet Oncol; 2023 Dec; 24(12):e458. PubMed ID: 38040000
[No Abstract] [Full Text] [Related]
16. Hyperthermic Intraperitoneal Chemotherapy in the Management of Primary Epithelial Ovarian Cancer: A Debated Issue for Gynecologic Oncologists.
Gadducci A; Cosio S; Lippolis PV
Anticancer Res; 2022 Oct; 42(10):4659-4665. PubMed ID: 36191972
[TBL] [Abstract][Full Text] [Related]
17. An overview and update of hyperthermic intraperitoneal chemotherapy in ovarian cancer.
de Bree E; Michelakis D
Expert Opin Pharmacother; 2020 Aug; 21(12):1479-1492. PubMed ID: 32486865
[TBL] [Abstract][Full Text] [Related]
18. Post-Publication Discussion Regarding Cytoreductive Surgery with or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer.
Cascales Campos PA; González Gil A
Ann Surg Oncol; 2022 May; 29(5):3361-3362. PubMed ID: 35254577
[No Abstract] [Full Text] [Related]
19. Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer.
Costales AB; Chambers L; Chichura A; Rose PG; Mahdi H; Michener CM; Yao M; Debernardo R
J Gynecol Obstet Hum Reprod; 2021 May; 50(5):101844. PubMed ID: 32590110
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal chemotherapy: Hot, timely, and relevant?
Mackay HJ; Kohn EC
Cancer; 2020 Dec; 126(24):5206-5209. PubMed ID: 32931026
[No Abstract] [Full Text] [Related]
[Next] [New Search]
